Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 10/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 3/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753838 | 0.86 | KDM4E (0.42) | PAX8ALDH1A1KDM4E | |
| SCHEMBL3777967 | 0.83 | SCN2A (0.32) | PAX8ALDH1A1KDM4E | |
| SCHEMBL17894521 | 0.83 | MIF (0.36) | PAX8 | |
| SCHEMBL3367109 | 0.83 | ESR1 (0.35) | SLC9A1ALDH1A1KDM4E | |
| SCHEMBL3396674 | 0.82 | SLC9A1 (0.36) | SLC9A1 | |
| SCHEMBL3362426 | 0.82 | ESR1 (0.35) | SLC9A1ALDH1A1 | |
| SCHEMBL3785117 | 0.82 | KMT2A (0.34) | PAX8ALDH1A1HSD17B10TDP1 | |
| SCHEMBL3363651 | 0.81 | MAPT (0.38) | SLC9A1ALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL15876020 | 0.81 | MAPT (0.39) | PAX8ALDH1A1 | |
| SCHEMBL3399526 | 0.80 | SLC9A1 (0.36) | SLC9A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745456-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-06-29 | — | — | US | disclosed |
| US-7410989-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410999-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | UNIVERSITY OF NORTH CAROLINIA AT CHAPEL HILL (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | The University of North Carolina at Chapel Hill: | 2008-03-06 | — | — | US | disclosed |
| EP-1399163-B1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIV NORTH CAROLINA (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1837024-A2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7241795-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070072877-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-29 | — | — | US | disclosed |
| US-20070072878-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-29 | — | — | US | disclosed |
| US-7183286-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-02-27 | — | — | US | disclosed |
| US-7163955-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-11 | — | — | US | disclosed |
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-23 | — | — | US | disclosed |
| US-20040235927-A1 | Synthesis and antimicrobial activity of novel dicationic \"reversed amidines\ | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| US-6737440-B2 | 2,5-BIS ((ALKYL (OR ARYL) IMINO) AMINOPHENYL) FURANS, THIOPHENES OR PYRROLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-05-18 | — | — | US | disclosed |
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-23 | — | — | US | disclosed |
| EP-1337510-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC \"REVERSED AMIDINES\ | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | GEORGIA STATE UNIVERSITY | 2003-05-01 | — | — | US | disclosed |
| WO-2002057224-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC 'REVERSED AMIDINES' | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | NQO2 858/4885SLC9A1 3290/4885PAX8 4408/4885 |
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | HRH4, TLR7, DDAH1 | NQO2 71/4885SLC9A1 1257/4885PAX8 3402/4885 |
| US-20040235927-A1 | Synthesis and antimicrobial activity of novel dicationic \"reversed amidines\ | HRH4, HDHD5, MRPS7 | NQO2 106/4885SLC9A1 1155/4885PAX8 3782/4885 |
| US-20070072878-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | NQO2 858/4885SLC9A1 3290/4885PAX8 4408/4885 |
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | NQO2 858/4885SLC9A1 3290/4885PAX8 4408/4885 |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | OAT, GYS2, HCCS | NQO2 858/4885SLC9A1 3290/4885PAX8 4408/4885 |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | TLR7, DHRS9, TLR8 | NQO2 441/4885SLC9A1 1339/4885PAX8 301/4885 |
| US-20070072877-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | NQO2 858/4885SLC9A1 3290/4885PAX8 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.